The document outlines various health-related news, including a measles outbreak in Texas and New Mexico, UNICEF's aid crisis ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

AstraZeneca said on Friday it will spend Ksh.323 billion on a research and development hub in Beijing, as the drugmaker ...

In a bold move to cement its foothold in China’s booming biopharmaceutical sector, AstraZeneca announced Friday a $2.5 billion investment in Beijing over the next five years. The pharmaceutical titan ...

AstraZeneca has announced a $2.5 billion investment in a research and development hub in Beijing, underscoring its commitment ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...

AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...